Reproducibility of dynamic contrast-enhanced MR imaging: Why we should care

Radiology

Volumn 266, Issue 3, 2013, Pages 698-700

  Goh, Vicky ^a,b   Schaeffter, Tobias ^a   Leach, Martin ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEDIRANIB; COMBRETASTATIN; GADOLINIUM;

COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DYNAMIC CONTRAST MATERIAL ENHANCED MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; IMAGING SOFTWARE; MAGNETIC RESONANCE ANGIOGRAPHY; MEASUREMENT ERROR; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; STANDARDIZATION; TUMOR VASCULARIZATION; UTERUS MYOMA;

CONTRAST MEDIA; FEMALE; HUMANS; LEIOMYOMA; MAGNETIC RESONANCE ANGIOGRAPHY; MODELS, BIOLOGICAL; PATTERN RECOGNITION, AUTOMATED; UTERINE NEOPLASMS;

EID: 84874321352     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12122447     Document Type: Review

References (10)

1. Messiou C, Orton M, Ang JE, et al. Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity. Radiology 2012;265(2): 426-436.
2. Nathan P, Zweifel M, Padhani AR, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res 2012;18(12): 3428-3439.
3. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005;92(9): 1599-1610.
4. Leach MO, Morgan B, Tofts PS, et al. Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging. Eur Radiol 2012;22(7): 1451-1464.
5. Quantitative Imaging Biomarkers Alliance. Profile: DCE MRI Quantification Version 1.6. Quantitative Imaging Biomarkers Alliance [serial online]. http://qibawiki.rsna.org/images /7/7b/DCEMRIProfile-v1-6-20111213.pdf. Published 2011. Accessed December 19, 2012.
6. Heye T, Davenport MS, Horvath JJ, et al. Reproducibility of dynamic contrast-enhanced MR imaging. I. Perfusion characteristics in the female pelvis by using multiple computer-aided diagnosis perfusion analysis solutions. Radiology 2013;266(3): 801-811.
7. Heye T, Merkle EM, Reiner CS, et al. Reproducibility of dynamic contrast-enhanced MR imaging. II. Comparison of intra- and interobserver variability with manual region of interest placement versus semiautomatic lesion segmentation and histogram analysis. Radiology 2013;266(3): 812-821.
8. Goh V, Halligan S, Bartram CI. Quantitative tumor perfusion assessment with multidetector CT: are measurements from two commercial software packages interchangeable? Radiology 2007;242(3): 777-782.
9. Goh V, Halligan S, Gharpuray A, Wellsted D, Sundin J, Bartram CI. Quantitative assessment of colorectal cancer tumor vascular parameters by using perfusion CT: influence of tumor region of interest. Radiology 2008;247(3): 726-732.
10. Miles KA, Lee TY, Goh V, et al. Current status and guidelines for the assessment of tumour vascular support with dynamic contrast- enhanced computed tomography. Eur Radiol 2012;22(7): 1430-1441.